Company Overview of Genentech, Inc.
Genentech, Inc., a biotechnology company, engages in the research, development, manufacture, and marketing of biotechnology products for treating patients with serious or life-threatening diseases in the United States. It offers molecular entities and medicines in the areas of oncology, immunology, neuroscience, metabolism, and infectious diseases. The company also offers hematology medicines that include antibody-drug conjugates, small molecule antagonists, and small molecule BCL-2 inhibitors. Genentech, Inc. has a strategic alliance with Array biopharma. The company was founded in 1976 and is headquartered in South San Francisco, California. Genentech, Inc. operates as a subsidiary of Roch...
1 DNA Way Mailstop 258A
South San Francisco, CA 94080-4990
Founded in 1976
Key Executives for Genentech, Inc.
Chief Executive Officer, Head of North American Commercial Operations and Director
Co-Founder and Member of Scientific Resource Board
Senior Vice President and General Counsel
Chief Compliance Officer, Head of Legal Affairs for North America, Senior Vice President and Secretary
Vice President of Human Resources and Regional Human Resources Head of North America
Compensation as of Fiscal Year 2014.
Genentech, Inc. Key Developments
Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People With Specific Type of Lung Cancer
May 13 15
Genentech announced positive results from two pivotal studies (NP28673 and NP28761) that showed alectinib, its oral investigational anaplastic lymphoma kinase (ALK) inhibitor, shrank tumors (overall response rate; ORR: 50.0% and 47.8%, respectively) in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed following treatment with crizotinib. In addition, alectinib was shown to shrink tumors in people whose cancer had spread to the central nervous system (CNS) (CNS ORR: 57.1% and 68.8%, respectively). People whose tumors shrank in response to alectinib continued to respond for a median of 11.2 and 7.5 months, respectively (duration of response; DOR). Alectinib demonstrated a safety profile consistent with that observed in previous studies. The most common adverse events (Grade 3 or higher occurring in at least 2% of people) were an increase in muscle enzymes (increased blood levels of creatine phosphokinase), increased liver enzymes and shortness of breath (dyspnea).
WaferGen Bio-systems, Inc. Announces Research Collaboration with Genentech Initiating its Early Access Program for Single Cell Genomics Technology
Apr 30 15
WaferGen Bio-systems, Inc. announced that the Company has signed a research collaboration with Genentech to evaluate and apply WaferGen's SmartChipTM platform in single cell sequencing. The joint work is aimed at validating the utility of the SmartChipTM technology for isolating single cells from various tissues and preparing libraries for Next-Generation Sequencing (NGS). Â Genentech represents WaferGen's initial partner in WaferGen's single cell genomics technology-focused Early Access Program. WaferGen successfully completed separate proof-of-concept studies related to isolating single cells with the SmartChipTM earlier this year with both the Broad Institute and BGI. At the throughput level scalable to several thousand cells per sample, the cell's genetic composition was successfully analyzed via the NGS method, thereby demonstrating increased discovery potential in a single workflow. WaferGen continues to believe that the SmartChipTM technology will be able to yield a 50-fold increase in the production of single cells per chip versus current technologies at a fraction of the per cell cost.
Genentech, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 02:30 PM
Apr 6 15
Genentech, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 02:30 PM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: Jacqueline Grant, Manager Business Development Neuroscience.
Similar Private Companies By Industry
Recent Private Companies Transactions